At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 135 enrolled
Drug / intervention
CequaTM (Cyclosporine 0.09%) ophthalmic solutiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Cequa™ in Subjects With Dry Eye Disease That Is Currently Inadequately Controlled While on Cyclosporine 0.05% Ophthalmic Emulsion
In Brief
A Phase 4 clinical trial evaluating CequaTM (Cyclosporine 0.09%) ophthalmic solution for Dry Eye Disease. Completed, enrolled 135 participants across 5 sites.
Detailed Summary
This is a Phase 4, multicenter, single arm, 12 week study in subjects with dry eye disease, which is inadequately controlled by cyclosporine 0.05% ophthalmic emulsion.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Disease
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedApr 2020
Enrollment StartJun 2020
Primary CompletionJun 2022
TodayJul 2026
First PostedApr 22, 2020
Enrollment StartJun 29, 2020
Primary CompletionJun 24, 2022
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 6.2 years ago
Interventions
CequaTM (Cyclosporine 0.09%) ophthalmic solutiondrug
One drop CequaTM (Cyclosporine 0.09%) ophthalmic solution in each eye twice daily, approximately 12 hours apart.